Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer (GO SOAR2)

NHS Grampian

Status

Enrolling

Conditions

Ovarian Cancer

Treatments

Other: no surgery

Procedure: interval cytoreductive surgery

Procedure: delayed cytoreductive surgery

Study type

Observational

Funder types

Other

Identifiers

NCT05523804

5719

Details and patient eligibility

About

To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.

Full description

Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following >5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.

Enrollment

800 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) or delayed (>5 cycles of chemotherapy) cytoreductive surgeries or no cytoreductive surgery (>5 cycles of chemotherapy alone.

Exclusion criteria

Women undergoing recurrent cytoreductive surgery.